Nutritional interventions for Alzheimer's prevention: A clinical precision medicine approach

Annals of the New York Academy of Sciences

Volumn 1367, Issue 1, 2016, Pages 50-56

  Schelke, Matthew W ^a   Hackett, Katherine ^a   Chen, Jaclyn L ^a   Shih, Chiashin ^a   Shum, Jessica ^a   Montgomery, Mary E ^b   Chiang, Gloria C ^a   Berkowitz, Cara ^a   Seifan, Alon ^c   Krikorian, Robert ^d   Isaacson, Richard Scott ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c Clinical Neurology   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's prevention; Clinical precision medicine; Insulin resistance; Nonpharmacological management; Nutrigenomics; Preclinical Alzheimer's disease

Indexed keywords

INSULIN;

ALZHEIMER DISEASE; ARTICLE; DIET THERAPY; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MOLECULAR PATHOLOGY; OXIDATIVE STRESS; PERSONALIZED MEDICINE; METABOLISM; NUTRITIONAL STATUS; PHYSIOLOGY; PROCEDURES; RISK REDUCTION; TRENDS;

ALZHEIMER DISEASE; HUMANS; INSULIN RESISTANCE; NUTRITIONAL STATUS; OXIDATIVE STRESS; PRECISION MEDICINE; RISK REDUCTION BEHAVIOR;

EID: 84964903247     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13070     Document Type: Article

References (62)

1. Wimo, A. et al. 2013. The worldwide economic impact of dementia 2010. Alzheimers Dement. 9: 1-11.
2. Sperling, R.A. et al. 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7: 280-292.
3. Tan, C.-C., J.-T. Yu & L. Tan . 2014. Biomarkers for preclinical Alzheimer's disease. J. Alzheimers Dis. 42: 1051-1069.
4. Anstey, K.J. et al. 2014. A self-report risk index to predict occurrence of dementia in three independent cohorts of older adults: the ANU-ADRI. PLoS One 9: e86141.
5. Sperling, R.A. et al. 2014. The A4 study: stopping AD before symptoms begin? Sci. Transl. Med. 6: 228fs13.
6. Shah, R. 2013. The role of nutrition and diet in Alzheimer disease: a systematic review. J. Am. Med. Dir. Assoc. 14: 398-402.
7. Dangour, A.D., P.J. Whitehouse, K. Rafferty, et al. 2010. B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review. J. Alzheimers Dis. 22: 205-224.
8. Middleton, L.E. & K. Yaffe . 2009. Promising strategies for the prevention of dementia. Arch. Neurol. 66: 1210-1215.
9. Hardy, J. & D. Allsop . 1991. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12: 383-388.
10. Spillantini, M.G. & M. Goedert . 1998. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21: 428-433.
11. Willette, A.A., B.B. Bendlin, E.J. Starks, et al. 2015. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol. 72: 1013.
12. Reaven, G.M. 1991. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am. Heart J. 121: 1283-1288.
13. Blass, J.P., R.K.-F. Sheu & G.E. Gibson . 2000. Inherent abnormalities in energy metabolism in Alzheimer disease: interaction with cerebrovascular compromise. Ann. N.Y. Acad. Sci. 903: 204-221.
14. Cheng, B. & M.P. Mattson . 1992. Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampus neurons: prevention by NGF and bFGF. Exp. Neurol. 117: 114-123.
15. Farris, W., S. Mansourian, Y. Chang, et al. 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 100: 4162-4167.
16. Mosconi, L., A. Pupi & M.J. De Leon . 2008. Brain glucose hypometabolism oxidative stress in preclinical Alzheimer's disease. Ann. N.Y. Acad. Sci. 1147: 180-195.
17. Costantini, L.C. et al. 2008. Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci. 9(Suppl. 2): S16.
18. Ehehalt, R., P. Keller, C. Haass, et al. 2003. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160: 113-123.
19. Cutler, R.G., J. Kelly, K. Storie, et al. 2004. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101: 2070-2075.
20. Wolozin, B. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57: 1439.
21. Fassbender, K., M. Simons, C. Bergmann, et al. 2001. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98: 5856-5861.
22. Lin, M.T. & M.F. Beal . 2006. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795.
23. Christen, Y. 2000. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71: 621S-629S.
24. Tamagno, E., M. Parola, P. Bardini, et al. 2005. β-Site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92: 628-636.
25. Pappolla, M.A., Y.J. Chyan, T.R. Omar, et al. 1998. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152: 871-877.
26. Yan, S.D., X. Chen, J. Fu, et al. 1996. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691.
27. Engelhart, M.J. 2002. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287: 3223.
28. Luchsinger, J.A., M.-X. Tang, S. Shea, et al. 2003. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 60: 203.
29. Craft, S. 2007. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4: 147-152.
30. Craft, S. 2005. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 26: 65-69.
31. Siu, A.L; U.S. Preventive Services Task Force. 2015. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 163: 861-868.
32. Van Himbergen, T.M. et al. 2012. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Arch. Neurol. 69: 594-600.
33. 11C] PiB-PET brain amyloid burden. PLoS One 7: e44260.
34. Matsuzaki, T. et al. 2010. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75: 764-770.
35. Ryan, M. 2000. Diabetes and the Mediterranean diet: a beneficial effect of oleic acid on insulin sensitivity, adipocyte glucose transport and endothelium-dependent vasoreactivity. QJM 93: 85-91.
36. Morris, M.C., C.C. Tangney, Y. Wang, et al. 2014. MIND diet score more predictive than DASH or Mediterranean diet scores. Alzheimers Dement. 10: P166.
37. Mastroiacovo, D. et al. 2015. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study-a randomized controlled trial. Am. J. Clin. Nutr. 101: 538-548.
38. Hawley, J.A. 2004. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab. Res. Rev. 20: 383-393.
39. Smith, J.C., K.A. Nielson, J.L. Woodard, et al. 2014. Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease. Front. Aging Neurosci. 6: 61.
40. Johnson, J.L., C.A. Slentz, J.A. Houmard, et al. 2007. Exercise training amount and intensity effects on metabolic syndrome (from studies of a targeted risk reduction intervention through defined exercise). Am. J. Cardiol. 100: 1759-1766.
41. Kivipelto, M. 2002. Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137: 149.
42. Di Paolo, G. & T.-W. Kim . 2011. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci. 12: 284-296.
43. Morris, M.C. 2004. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J. Neurol. Neurosurg. Psychiatry 75: 1093-1099.
44. Kamanna, V.S. & M.L. Kashyap . 2008. Mechanism of action of niacin. Am. J. Cardiol. 101: 20B-26B.
45. Caramelli, P., R. Nitrini, R. Maranhão, et al. 1999. Increased apolipoprotein B serum concentration in Alzheimer's disease. Acta Neurol. Scand. 100: 61-63.
46. Fotuhi, M., P. Mohassel & K. Yaffe . 2009. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat. Clin. Pract. Neurol. 5: 140-152.
47. Lim, G.P. 2005. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25: 3032-3040.
48. Harris, W.S., M. Miller, A.P. Tighe, et al. 2008. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197: 12-24.
49. Coyle, J. & P. Puttfarcken . 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695.
50. Uttara, B., A. Singh, P. Zamboni, et al. 2009. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7: 65-74.
51. Masaki, K.H., K.G. Losonczy, G. Izmirlian, et al. 2000. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54: 1265-1272.
52. Joseph, J.A., G. Arendash, M. Gordon, et al. 2003. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr. Neurosci. 6: 153-162.
53. Krikorian, R., M.D. Shidler, T.A. Nash, et al. 2010. Blueberry supplementation improves memory in older adults. J. Agric. Food Chem. 58: 3996-4000.
54. Lim, G.P., T. Chu, F. Yang, et al. 2001. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21: 8370-8377.
55. Baum, L., C.W.K. Lam, S.K.-K. Cheung, et al. 2008. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 28: 110-113.
56. Cole, G.M., G.P. Lim, F. Yang, et al. 2005. Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol. Aging 26: 133-136.
57. Ho, P.I., D. Ortiz, E. Rogers & T.B. Shea . 2002. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J. Neurosci. Res. 70: 694-702.
58. Morris, M.S. 2003. Homocysteine and Alzheimer's disease. Lancet Neurol. 2: 425-428.
59. Smith, A.D. et al. 2010. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 5: e12244.
60. Peng, Q. et al. 2015. The MTHFR C677T polymorphism contributes to increased risk of Alzheimer's disease: evidence based on 40 case-control studies. Neurosci. Lett. 586: 36-42.
61. Hustad, S. et al. 2007. The methylenetetrahydrofolate reductase 677C→ T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. Am. J. Hum. Genet. 80: 846-855.
62. Seifan, A. & R.S. Isaacson . 2015. The Alzheimer's prevention clinic at Weill Cornell Medical College/New York-Presbyterian Hospital: risk stratification and personalized early intervention. J. Prev. Alzheimers Dis. 2: 254-266.